(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
The Job of a Land Legal counselor in Property Exchanges - 2US FDA grants market authorization to six on! PLUS nicotine pouch products
- 3West Antarctica’s history of rapid melting foretells sudden shifts in continent’s ‘catastrophic’ geology
- 4Astronomer captures 2 meteors slamming into the moon (video)
- 5Savvy Cleaning: The 6 Robot Vacuums of 2024
- Holiday season sees uptick in norovirus cases, according to CDC
- Islamabad: Iran allows 20 Pakistani ships through Strait of Hormuz
- The race to mine the moon is on – and it urgently needs some clear international rules
- NASA says Maven spacecraft that was orbiting Mars has gone silent
- The Best 20 Tunes that Characterized an Age
- Figure out How to Amplify Innovation and Infotainment Frameworks for Senior Drivers in SUVs
- Remote Headphones: Upgrade Your Sound Insight
- Top notch DSLR Cameras for Photography Devotees
- Figure out How to Explore Your Direction to the Best Dental Embed Trained professional: A Far reaching Manual
